Sarclisa was administered subcutaneously via an on-body delivery system (OBDS) in the investigational, randomized, open-label clinical trial and demonstrated that compared with IV treatment, patients ...
If that does happen, HER2 inhibitor Enhertu could become the first drug in the antibody-drug conjugate (ADC) class to be delivered subcutaneously – which is a tall order for such a large ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback